Skip to main content
SpringerLink
Log in

Pathology

  • Chapter
  • First Online:
Non-Hodgkin's Lymphoma in Childhood and Adolescence

Abstract

Non-Hodgkin’s lymphomas (NHL) of children and young adults differ considerably in biology, incidence, treatment, and outcome compared to lymphomas occurring in adults. They constitute a diverse spectrum of usually highly aggressive tumors derived from both mature and immature lymphoid cells. The diagnosis is accomplished by combining histomorphologic, immunophenotypic, and genetic features into specific lymphoma subtypes. Besides the classical high-grade lymphomas arising preferentially in the pediatric population, such as Burkitt lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma (ALCL), reports of several unique clinicopathologic lymphomatous conditions with a rather benign clinical course have occurred in increasing numbers, which have eventually led to the acknowledgment as separate entities in the updated WHO 2016 classification of tumors of the hematopoietic and lymphoid tissues. Among T-cell lymphomas, more precisely characterized genetic and phenotypic peculiarities of ALCL and peripheral T-cell lymphoma (PTCL) have led to distinct subcategorization with evidence of clinical importance. Exact pathologic diagnosis provides the basis for therapeutic management and risk stratification. Here, we describe characteristic pathologic features of lymphomas arising in the pediatric age group, with on one hand emphasis on the most common subtypes, on the other hand with description of the most important diagnostic features and the differential diagnosis of the newly recognized entities, such as pediatric-type follicular- and marginal-zone lymphoma, as well as large B-cell lymphomas with IRF-4 rearrangements.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow S, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.

    Google Scholar 

  2. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med. 1996;334(19):1238–48.

    Article  CAS  PubMed  Google Scholar 

  3. Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2001;15(1):51–95, vi.

    Article  CAS  PubMed  Google Scholar 

  4. Lin P, Jones D, Dorfman DM, Medeiros LJ. Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol. 2000;24(11):1480–90.

    Article  CAS  PubMed  Google Scholar 

  5. Tricot G, Broeckaert-Van Orshoven A, Van Hoof A, Verwilghen RL. Sudan black B positivity in acute lymphoblastic leukaemia. Br J Haematol. 1982;51(4):615–21.

    Article  CAS  PubMed  Google Scholar 

  6. Perkins SL, Segal GH, Kjeldsberg CR. Classification of non-Hodgkin’s lymphomas in children. Semin Diagn Pathol. 1995;12(4):303–13.

    CAS  PubMed  Google Scholar 

  7. Oschlies I, Burkhardt B, Chassagne-Clement C, d’Amore ES, Hansson U, Hebeda K, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011;35(6):836–44.

    Article  PubMed  Google Scholar 

  8. Arber DA, Snyder DS, Fine M, Dagis A, Niland J, Slovak ML. Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. Am J Clin Pathol. 2001;116(1):25–33.

    Article  CAS  PubMed  Google Scholar 

  9. Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol. 1981;48(2):179–97.

    Article  CAS  PubMed  Google Scholar 

  10. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.

    CAS  PubMed  Google Scholar 

  11. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014073.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99(2):627–33.

    Article  CAS  PubMed  Google Scholar 

  13. Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186(2):140–3.

    Article  CAS  PubMed  Google Scholar 

  14. Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 1997;90(1):28–35.

    CAS  PubMed  Google Scholar 

  15. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chantepie SP, Cornet E, Salaun V, Reman O. Hematogones: an overview. Leuk Res. 2013;37(11):1404–11.

    Article  CAS  PubMed  Google Scholar 

  17. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98(8):2498–507.

    Article  CAS  PubMed  Google Scholar 

  18. Al-Shieban S, Byrne E, Trivedi P, Morilla R, Matutes E, Naresh KN. Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients. Br J Haematol. 2011;154(4):466–70.

    Article  PubMed  Google Scholar 

  19. Yasmeen S, Rajkumar A, Grossman H, Szallasi A. Terminal deoxynucleotidyl transferase (TdT)-negative lymphoblastic leukemia in pediatric patients: incidence and clinical significance. Pediatr Dev Pathol. 2017;20:463–8.

    Article  PubMed  Google Scholar 

  20. Adam P, Hakroush S, Hofmann I, Reidenbach S, Marx A, Strobel P. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall. Virchows Arch. 2014;465(3):313–20.

    Article  CAS  PubMed  Google Scholar 

  21. Ohgami RS, Zhao S, Ohgami JK, Leavitt MO, Zehnder JL, West RB, et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2012;36(11):1619–28.

    Article  PubMed  Google Scholar 

  22. Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, et al. Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. Am J Surg Pathol. 2014;38(9):1298–304.

    Article  PubMed  Google Scholar 

  23. Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol. 2013;20(3):137–40.

    Article  CAS  PubMed  Google Scholar 

  24. van der Velden VH, Bruggemann M, Hoogeveen PG, de Bie M, Hart PG, Raff T, et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia. 2004;18(12):1971–80.

    Article  CAS  PubMed  Google Scholar 

  25. Szczepanski T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood. 1999;93(12):4079–85.

    CAS  PubMed  Google Scholar 

  26. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3407–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Miles RR, Shah RK, Frazer JK. Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173(4):582–96.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20(9):1496–510.

    Article  CAS  PubMed  Google Scholar 

  29. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156(6):744–56.

    Article  CAS  PubMed  Google Scholar 

  30. Barth TF, Muller S, Pawlita M, Siebert R, Rother JU, Mechtersheimer G, et al. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt’s lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. J Pathol. 2004;203(4):940–5.

    Article  CAS  PubMed  Google Scholar 

  31. Magrath I. The pathogenesis of Burkitt’s lymphoma. Adv Cancer Res. 1990;55:133–270.

    Article  CAS  PubMed  Google Scholar 

  32. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144(1):24–40.

    Article  PubMed  Google Scholar 

  33. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, et al. Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology. 2008;52(4):427–35.

    Article  PubMed  Google Scholar 

  34. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, et al. Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol. 2003;120(4):660–70.

    Article  PubMed  Google Scholar 

  35. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46(197):218–23.

    Article  CAS  PubMed  Google Scholar 

  36. Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18(21):3707–21.

    Article  CAS  PubMed  Google Scholar 

  37. Woo KB, Funkhouser WK, Sullivan C, Alabaster O. Analysis of the proliferation kinetics of Burkitt’s lymphoma cells. Cell Tissue Kinet. 1980;13(6):591–604.

    CAS  PubMed  Google Scholar 

  38. Perkins SL. Work-up and diagnosis of pediatric non-Hodgkin’s lymphomas. Pediatr Dev Pathol. 2000;3(4):374–90.

    Article  CAS  PubMed  Google Scholar 

  39. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.

    Article  CAS  PubMed  Google Scholar 

  40. Lones MA, Auperin A, Raphael M, McCarthy K, Perkins SL, MacLennan KA, et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol. 2000;11(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  41. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.

    Article  CAS  PubMed  Google Scholar 

  42. Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32(1):113–22.

    Article  PubMed  Google Scholar 

  43. Cogliatti SB, Novak U, Henz S, Schmid U, Moller P, Barth TF, et al. Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol. 2006;134(3):294–301.

    Article  CAS  PubMed  Google Scholar 

  44. Naresh KN, Ibrahim HA, Lazzi S, Rince P, Onorati M, Ambrosio MR, et al. Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries. Br J Haematol. 2011;154(6):770–6.

    Article  PubMed  Google Scholar 

  45. Tapia G, Lopez R, Munoz-Marmol AM, Mate JL, Sanz C, Marginet R, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59(4):672–8.

    Article  PubMed  Google Scholar 

  46. Masque-Soler N, Szczepanowski M, Kohler CW, Aukema SM, Nagel I, Richter J, et al. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Br J Haematol. 2015;171(4):501–8.

    Article  CAS  PubMed  Google Scholar 

  47. Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1986;83(9):2984–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006;107(5):1084–92.

    Article  PubMed  Google Scholar 

  49. Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, et al. The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Arch. 2017;471(4):453–66.

    Article  PubMed  Google Scholar 

  51. Rymkiewicz G, Grygalewicz B, Chechlinska M, Blachnio K, Bystydzienski Z, Romejko-Jarosinska J, et al. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Mod Pathol. 2018;31(5):732–43.

    Article  CAS  PubMed  Google Scholar 

  52. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121(3):384–92.

    Article  PubMed  Google Scholar 

  53. Cairo MS, Sposto R, Hoover-Regan M, Meadows AT, Anderson JR, Siegel SE, et al. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol. 2003;72(1):53–63.

    Article  PubMed  Google Scholar 

  54. Preciado MV, Fallo A, Chabay P, Calcagno L, De Matteo E. Epstein Barr virus-associated lymphoma in HIV-infected children. Pathol Res Pract. 2002;198(5):327–32.

    Article  PubMed  Google Scholar 

  55. Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 2017;35(9):1018–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997;89(7):2291–7.

    CAS  PubMed  Google Scholar 

  57. Dargent JL, Meiers I, Lespagnard L, Ma Y, Dehou MF, Verhest A. Diffuse large B-cell lymphoma with fibrillary matrix. Diagn Cytopathol. 2002;27(4):223–6.

    Article  PubMed  Google Scholar 

  58. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.

    Article  PubMed  Google Scholar 

  59. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

    Article  CAS  PubMed  Google Scholar 

  60. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369–74.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.

    Article  CAS  PubMed  Google Scholar 

  64. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7.

    Article  CAS  PubMed  Google Scholar 

  65. Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015;16(15):e555–e67.

    Article  CAS  PubMed  Google Scholar 

  66. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615–33.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Sebastian E, Alcoceba M, Balanzategui A, Marin L, Montes-Moreno S, Flores T, et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am J Pathol. 2012;181(5):1879–88.

    Article  CAS  PubMed  Google Scholar 

  69. Dobashi A. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):71–8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Pasqualucci L, Bereshchenko O, Niu H, Klein U, Basso K, Guglielmino R, et al. Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk Lymphoma. 2003;44(Suppl 3):S5–12.

    Article  CAS  PubMed  Google Scholar 

  71. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98(2):255–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99(7):2285–90.

    Article  CAS  PubMed  Google Scholar 

  73. Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119(16):3757–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107(10):4047–52.

    Article  CAS  PubMed  Google Scholar 

  76. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d’Amore ES, Szczepanowski M, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262–8.

    Article  PubMed  Google Scholar 

  78. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411–21.

    Article  PubMed  Google Scholar 

  80. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015;125(1):33–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Dunleavy K, Steidl C. Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. Semin Hematol. 2015;52(2):119–25.

    Article  PubMed  Google Scholar 

  82. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9.

    Article  CAS  PubMed  Google Scholar 

  83. Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors JM, et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling. Am J Surg Pathol. 2015;39(10):1322–30.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Moller P, Moldenhauer G, Momburg F, Lammler B, Eberlein-Gonska M, Kiesel S, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69(4):1087–95.

    CAS  PubMed  Google Scholar 

  85. Garcia JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Perez-Guillermo M, et al. Large B-cell lymphoma with Hodgkin’s features. Histopathology. 2005;47(1):101–10.

    Article  CAS  PubMed  Google Scholar 

  86. Pileri SA, Gaidano G, Zinzani PL, Falini B, Gaulard P, Zucca E, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162(1):243–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45(6):619–24.

    Article  CAS  PubMed  Google Scholar 

  88. Copie-Bergman C, Gaulard P, Maouche-Chretien L, Briere J, Haioun C, Alonso MA, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10):3567–75.

    CAS  PubMed  Google Scholar 

  89. Gentry M, Bodo J, Durkin L, Hsi ED. Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma. Am J Surg Pathol. 2017;41(2):189–94.

    Article  PubMed  Google Scholar 

  90. Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2008;2008:349–58.

    Article  Google Scholar 

  91. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157–63.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer. 2007;46(4):406–15.

    Article  CAS  PubMed  Google Scholar 

  93. Eberle FC, Salaverria I, Steidl C, Summers TA Jr, Pittaluga S, Neriah SB, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558–66.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013;37(3):333–43.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Louissaint A Jr, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012;120(12):2395–404.

    Article  CAS  PubMed  Google Scholar 

  97. Agrawal R, Wang J. Pediatric follicular lymphoma: a rare clinicopathologic entity. Arch Pathol Lab Med. 2009;133(1):142–6.

    PubMed  Google Scholar 

  98. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, et al. Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica. 2010;95(2):253–9.

    Article  PubMed  Google Scholar 

  99. Quintanilla-Martinez L, Sander B, Chan JK, Xerri L, Ott G, Campo E, et al. Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch. 2016;468(2):141–57.

    Article  CAS  PubMed  Google Scholar 

  100. Lorsbach RB, Shay-Seymore D, Moore J, Banks PM, Hasserjian RP, Sandlund JT, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99(6):1959–64.

    Article  CAS  PubMed  Google Scholar 

  101. Karnik T, Ozawa MG, Lefterova M, Luna-Fineman S, Alvarez E, Link M, et al. The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. Hum Pathol. 2015;46(4):629–33.

    Article  CAS  PubMed  Google Scholar 

  102. Martin-Guerrero I, Salaverria I, Burkhardt B, Szczepanowski M, Baudis M, Bens S, et al. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica. 2013;98(8):1237–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balague O, et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016;128(8):1101–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Louissaint A Jr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Schmidt J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C, et al. Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood. 2017;130(3):323–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol. 2004;121(4):464–72.

    Article  PubMed  Google Scholar 

  107. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–47.

    Article  CAS  PubMed  Google Scholar 

  108. de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Briere J, et al. Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: a GELA study. Ann Oncol. 2012;23(12):3143–51.

    Article  PubMed  Google Scholar 

  109. Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003;27(4):522–31.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Rizzo KA, Streubel B, Pittaluga S, Chott A, Xi L, Raffeld M, et al. Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR. Mod Pathol. 2010;23(6):866–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kluin PM, Langerak AW, Beverdam-Vincent J, Geurts-Giele WR, Visser L, Rutgers B, et al. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder? J Pathol. 2015;236(3):302–14.

    Article  CAS  PubMed  Google Scholar 

  112. Attygalle AD, Liu H, Shirali S, Diss TC, Loddenkemper C, Stein H, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104(10):3343–8.

    Article  CAS  PubMed  Google Scholar 

  113. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4.

    Article  CAS  PubMed  Google Scholar 

  114. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89(4):1394–404.

    CAS  PubMed  Google Scholar 

  115. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591–8.

    CAS  PubMed  Google Scholar 

  116. Alessandri AJ, Pritchard SL, Schultz KR, Massing BG. A population-based study of pediatric anaplastic large cell lymphoma. Cancer. 2002;94(6):1830–5.

    Article  PubMed  Google Scholar 

  117. Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  118. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–706.

    CAS  PubMed  Google Scholar 

  119. Kadin ME. Anaplastic large cell lymphoma and its morphological variants. Cancer Surv. 1997;30:77–86.

    CAS  PubMed  Google Scholar 

  120. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91(6):2076–84.

    CAS  PubMed  Google Scholar 

  121. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol. 1998;153(3):875–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Pileri SA, Pulford K, Mori S, Mason DY, Sabattini E, Roncador G, et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol. 1997;150(4):1207–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol. 1993;17(9):859–68.

    Article  CAS  PubMed  Google Scholar 

  124. Vassallo J, Lamant L, Brugieres L, Gaillard F, Campo E, Brousset P, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin’s lymphoma: report of 10 cases. Am J Surg Pathol. 2006;30(2):223–9.

    Article  PubMed  Google Scholar 

  125. Hodges KB, Collins RD, Greer JP, Kadin ME, Kinney MC. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: pathologic and clinical features. Am J Surg Pathol. 1999;23(1):49–58.

    Article  CAS  PubMed  Google Scholar 

  126. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.

    CAS  PubMed  Google Scholar 

  127. Penny RJ, Blaustein JC, Longtine JA, Pinkus GS. Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases. Cancer. 1991;68(2):362–73.

    Article  CAS  PubMed  Google Scholar 

  128. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88(10):4005–11.

    CAS  PubMed  Google Scholar 

  129. Brousset P, Rochaix P, Chittal S, Rubie H, Robert A, Delsol G. High incidence of Epstein-Barr virus detection in Hodgkin’s disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology. 1993;23(2):189–91.

    Article  CAS  PubMed  Google Scholar 

  130. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20(40):5623–37.

    Article  CAS  PubMed  Google Scholar 

  131. Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin’s lymphoma. Br J Haematol. 2001;113(2):275–95.

    Article  CAS  PubMed  Google Scholar 

  132. Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61(23):2939–53.

    Article  CAS  PubMed  Google Scholar 

  133. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199(3):330–58.

    Article  CAS  PubMed  Google Scholar 

  134. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001;114(4):741–60.

    Article  CAS  PubMed  Google Scholar 

  135. Oschlies I, Lisfeld J, Lamant L, Nakazawa A, d’Amore ES, Hansson U, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98(1):50–6.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Onaindia A, Montes-Moreno S, Rodriguez-Pinilla SM, Batlle A, Gonzalez de Villambrosia S, Rodriguez AM, et al. Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology. 2015;66(6):846–55.

    Article  PubMed  Google Scholar 

  137. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Karai LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37(8):1173–81.

    Article  PubMed  Google Scholar 

  139. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102(7):2642–4.

    Article  CAS  PubMed  Google Scholar 

  140. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997;89(5):1483–90.

    CAS  PubMed  Google Scholar 

  141. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23.

    Article  CAS  PubMed  Google Scholar 

  142. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013;85(2):206–15.

    Article  PubMed  Google Scholar 

  143. Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, Vergier B, Jouary T, Beylot-Barry M, et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 2010;130(3):816–25.

    Article  CAS  PubMed  Google Scholar 

  144. Mellgren K, Attarbaschi A, Abla O, Alexander S, Bomken S, Bubanska E, et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Ann Hematol. 2016;95(8):1295–305.

    Article  CAS  PubMed  Google Scholar 

  145. Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group. Br J Haematol. 2015;168(6):835–44.

    Article  CAS  PubMed  Google Scholar 

  146. Windsor R, Stiller C, Webb D. Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer. 2008;50(4):784–7.

    Article  PubMed  Google Scholar 

  147. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2006;2006:317–22.

    Article  Google Scholar 

  148. Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens. 2018;7(1):28.

    Article  PubMed Central  Google Scholar 

  149. Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96(2):443–51.

    CAS  PubMed  Google Scholar 

  150. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261–9.

    Article  CAS  PubMed  Google Scholar 

  151. Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES. Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer. 2013;60(7):1165–70.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Oschlies I, Simonitsch-Klupp I, Maldyk J, Konovalov D, Abramov D, Myakova N, et al. Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome. Br J Dermatol. 2015;172(3):793–7.

    Article  CAS  PubMed  Google Scholar 

  153. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838–45.

    Article  CAS  PubMed  Google Scholar 

  154. Pincus LB, LeBoit PE, McCalmont TH, Ricci R, Buzio C, Fox LP, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities? Am J Dermatopathol. 2009;31(6):520–6.

    Article  PubMed  Google Scholar 

  155. Rodriguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, Tomas IE, Almagro M, Sevilla A, et al. TCR-gamma expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37(3):375–84.

    Article  PubMed  Google Scholar 

  156. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol. 2009;22(6):753–61.

    Article  CAS  PubMed  Google Scholar 

  157. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007;50(4):498–508.

    Article  CAS  PubMed  Google Scholar 

  158. Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood. 1994;84(8):2640–8.

    CAS  PubMed  Google Scholar 

  159. Cortes JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol. 2016;23(4):434–43.

    Article  CAS  PubMed  Google Scholar 

  160. Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF, Pediatric Heart Transplant Study. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant. 2012;12(11):3061–8.

    Article  CAS  PubMed  Google Scholar 

  161. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54; quiz.

    Article  CAS  PubMed  Google Scholar 

  162. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367(9506):233–9.

    Article  PubMed  Google Scholar 

  163. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21(6):476–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–52.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Ramos E, Hernandez F, Andres A, Martinez-Ojinaga E, Molina M, Sarria J, et al. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome. Pediatr Transplant. 2013;17(5):472–8.

    Article  PubMed  Google Scholar 

  166. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, van der Heide JJ H, Veeger NJ, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transpl. 2005;19(3):327–34.

    Article  Google Scholar 

  167. Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. Am J Clin Pathol. 2012;138(4):568–78.

    Article  PubMed  Google Scholar 

  168. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12(6):383–94.

    Article  PubMed  Google Scholar 

  169. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007;38(2):315–25.

    Article  PubMed  Google Scholar 

  170. Lones MA, Mishalani S, Shintaku IP, Weiss LM, Nichols WS, Said JW. Changes in tonsils and adenoids in children with posttransplant lymphoproliferative disorder: report of three cases with early involvement of Waldeyer’s ring. Hum Pathol. 1995;26(5):525–30.

    Article  CAS  PubMed  Google Scholar 

  171. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85(2):552–65.

    CAS  PubMed  Google Scholar 

  172. Pitman SD, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Berdeja JG, et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol. 2006;30(4):470–6.

    Article  PubMed  Google Scholar 

  173. Chetty R, Biddolph S, Gatter K. An immunohistochemical analysis of Reed-Sternberg-like cells in posttransplantation lymphoproliferative disorders: the possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin’s disease and Reed-Sternberg-like cells in non-Hodgkin’s lymphomas and reactive conditions. Hum Pathol. 1997;28(4):493–8.

    Article  CAS  PubMed  Google Scholar 

  174. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–83.

    Article  PubMed  PubMed Central  Google Scholar 

  175. Gibson SE, Swerdlow SH, Craig FE, Surti U, Cook JR, Nalesnik MA, et al. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder? Am J Surg Pathol. 2011;35(6):807–15.

    Article  PubMed  Google Scholar 

  176. Wistinghausen B, Gross TG, Bollard C. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatr Hematol Oncol. 2013;30(6):520–31.

    Article  CAS  PubMed  Google Scholar 

  177. Herreman A, Dierickx D, Morscio J, Camps J, Bittoun E, Verhoef G, et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma. 2013;54(10):2190–9.

    Article  CAS  PubMed  Google Scholar 

  178. Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, et al. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. 2016;7(25):37636–48.

    Article  PubMed  PubMed Central  Google Scholar 

  179. Swerdlow SH, Jaffe ES, Brousset P, Chan JK, de Leval L, Gaulard P, et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38(10):e60–71.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Sivaraman P, Lye WC. Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed Pharmacother. 2001;55(7):366–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Medical University of Vienna, Vienna, Austria

    Christoph Kornauth, Ana-Iris Schiefer & Ingrid Simonitsch-Klupp

Authors
  1. Christoph Kornauth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana-Iris Schiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingrid Simonitsch-Klupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingrid Simonitsch-Klupp .

Editor information

Editors and Affiliations

  1. University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada

    Oussama Abla

  2. Medical University of Vienna, St. Anna Children’s Hospital, Vienna, Wein, Austria

    Andishe Attarbaschi

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kornauth, C., Schiefer, AI., Simonitsch-Klupp, I. (2019). Pathology. In: Abla, O., Attarbaschi, A. (eds) Non-Hodgkin's Lymphoma in Childhood and Adolescence. Springer, Cham. https://doi.org/10.1007/978-3-030-11769-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11769-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11768-9

  • Online ISBN: 978-3-030-11769-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation